본문 바로가기

Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
Cancer Research and Treatment47(4) · pp.661 · 2015
피인용
Web of Science 21KCI 3
JCR IF
JCR 2014 3.318
ISSN
1598-2998

저자

  1. 윤성훈제1저자전남대학교
  2. 최유덕전남대학교
  3. 오인재전남대학교
  4. 김규식전남대학교
  5. 최하영전남대학교
  6. 장진선전남대학교
  7. 신홍준전남대학교
  8. 박철규전남대학교
  9. 김영철교신저자전남대학교

초록

Purpose Direct sequencing (DS) is the standard method for detection of epidermal growth factor receptor (EGER) gene mutation in non-small cell lung cancer (NSCLC); however, low detection sensitivity is a problem. The aim of this study is to demonstrate higher detection rate of EGER gene mutation with peptide nucleic acid (PNA) clamping compared with DS. Materials and Methods This is a single arm, prospective study for patients with stage III B/IV or relapsed NSCLC. Using tumor DNA from 138 patients, both DS and PNA clamping for EGER gene in exon 18, 19, 20, and 21 were performed. Discrepant results between the two methods were verified using Cobas and a mutant enrichment based next generation sequencing (NGS). Patients with activating mutations were treated with EGFR tyrosine kinase inhibitor (EGFR-TKI, gefi tinib, or erlotinib) as first line treatment. Results Of 138 paired test sets, 24 (17.4%) and 45 (32.6%) cases with activating mutations were detected by DS and PNA clamping, respectively. The difference of detection rate between the two methods was 15.2% (95% confidence interval, 8.7% to 17.8%; p < 0.001). Between the two methods, 25 cases showed discrepant results (n=23, PNA+/DS-; n=2, PNA-/DS+). Mutations were confirmed by Cobas or NGS in 22 of 23 PNA+/DS- cases. The response rates to EGFR-TKI were 72.2% in the PNA+/DS+ group and 85.0% in the PNA+/DS- group. Conclusion PNA clamping showed a significantly higher detection rate of EGER gene mutation compared with DS. Higher sensitivity of PNA clamping was not compromised by the loss of predictive power of response to EGFR-TKI.

키워드

GeneserbB-1MutationPeptide nucleic acidsTYROSINE KINASE INHIBITORPOLYMERASE-CHAIN-REACTIONOPEN-LABELACQUIRED-RESISTANCE1ST-LINE TREATMENTGEFITINIBTIMECHEMOTHERAPYSPECIMENSERLOTINIB

식별자

WoS UID
000362895800015
KCI
ART002039749